|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/12/14 Biolase, Inc 10-Q 3/31/14 64:5.6M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 414K
2: EX-10 Ex-10.1 HTML 43K
3: EX-10 Ex-10.2 HTML 26K
4: EX-31 Ex-31.1 HTML 26K
5: EX-31 Ex-31.2 HTML 26K
6: EX-32 Ex-32.1 HTML 20K
7: EX-32 Ex-32.2 HTML 20K
44: R1 Document and Entity Information HTML 41K
34: R2 Consolidated Balance Sheets HTML 116K
42: R3 Consolidated Balance Sheets (Parenthetical) HTML 45K
46: R4 Consolidated Statements Of Operations And HTML 88K
Comprehensive Loss
59: R5 Consolidated Statements Of Cash Flows HTML 124K
36: R6 Description of Business and Basis of Presentation HTML 44K
41: R7 Summary of Significant Accounting Policies HTML 28K
31: R8 Stock-Based Awards and Per Share Information HTML 119K
23: R9 Inventory HTML 34K
60: R10 Property, Plant, and Equipment HTML 50K
48: R11 Intangible Assets and Goodwill HTML 72K
47: R12 Accrued Liabilities and Deferred Revenue HTML 67K
52: R13 Lines Of Credit and Other Borrowings HTML 33K
53: R14 Commitments and Contingencies HTML 47K
51: R15 Segment Information HTML 37K
54: R16 Concentrations HTML 24K
43: R17 Income Taxes HTML 27K
45: R18 Subsequent Event HTML 27K
50: R19 Accounting Policies (Policies) HTML 80K
64: R20 Stock-Based Awards and Per Share Information HTML 117K
(Tables)
56: R21 Inventory (Tables) HTML 32K
38: R22 Property, Plant, and Equipment (Tables) HTML 48K
49: R23 Intangible Assets and Goodwill (Tables) HTML 65K
40: R24 Accrued Liabilities and Deferred Revenue (Tables) HTML 72K
19: R25 Segment Information (Tables) HTML 30K
57: R26 Description of Business and Basis of Presentation HTML 63K
- Additional Information (Detail)
61: R27 Stock-Based Awards and Per Share Information - HTML 53K
Additional Information (Detail)
27: R28 Classification of Compensation Expense Associated HTML 27K
with Share-Based Payments (Detail)
26: R29 Assumptions Used in Estimating Fair Value of Stock HTML 30K
Options Granted (Detail)
29: R30 Summary of Option Activity (Detail) HTML 72K
30: R31 Cash Proceeds Along with Fair Value Disclosures HTML 34K
Related to Grants, Exercises, and Vesting Options
(Detail)
32: R32 Components of Inventory (Detail) HTML 30K
18: R33 Inventory - Additional Information (Detail) HTML 23K
55: R34 Components of Property, Plant and Equipment HTML 39K
(Detail)
37: R35 Property, Plant, and Equipment - Additional HTML 22K
Information (Detail)
39: R36 Intangible Assets and Goodwill - Additional HTML 22K
Information (Detail)
21: R37 Summary of Intangible Assets, Related Accumulated HTML 47K
Amortization and Goodwill (Detail)
63: R38 Components of Accrued Liabilities (Detail) HTML 44K
14: R39 Changes in Initial Product Warranty Accrual and HTML 35K
Expenses Under Initial and Extended Warranties
(Detail)
33: R40 Summary of Deferred Revenue (Detail) HTML 35K
58: R41 Lines of Credit and Other Borrowings - Additional HTML 73K
Information (Detail)
20: R42 Commitments and Contingencies - Additional HTML 34K
Information (Detail)
25: R43 Segment Information - Additional Information HTML 28K
(Detail)
28: R44 Summary of Net Revenue by Geographic Location HTML 23K
(Detail)
35: R45 Concentrations - Additional Information (Detail) HTML 30K
16: R46 Income Taxes - Additional Information (Detail) HTML 31K
22: R47 Subsequent Event - Additional Information (Detail) HTML 30K
62: XML IDEA XML File -- Filing Summary XML 91K
15: EXCEL IDEA Workbook of Financial Reports XLSX 104K
24: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 739K
8: EX-101.INS XBRL Instance -- biol-20140331 XML 988K
10: EX-101.CAL XBRL Calculations -- biol-20140331_cal XML 134K
11: EX-101.DEF XBRL Definitions -- biol-20140331_def XML 663K
12: EX-101.LAB XBRL Labels -- biol-20140331_lab XML 874K
13: EX-101.PRE XBRL Presentations -- biol-20140331_pre XML 751K
9: EX-101.SCH XBRL Schema -- biol-20140331 XSD 136K
17: ZIP XBRL Zipped Folder -- 0001564590-14-002044-xbrl Zip 110K
Exhibit 31.1
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Federico Pignatelli, certify that:
1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2014 of BIOLASE, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: May 12, 2014 |
By: |
|
|
|
|
|
|
Chief Executive Officer (Principal Executive Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/12/14 | 8-K | ||
| For Period end: | 3/31/14 | |||
| List all Filings | ||||